Drugs / MVA Multi-Filo Ebola Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03583606 | Nov 2018 → Jan 2020 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02891980 | Mar 2017 → Mar 2019 | Ebola hemorrhagic fever, Marburg hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA Multi-Filo Ebola Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02891980 ↗ |
| Modality | Vaccine | “MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines” NCT02891980 ↗ |
| Route | Intramuscular | “IM injection into the deltoid” NCT03583606 ↗ |